Iter-4360dd15-0062-pubmed-title-verification-10-pmids

第 62 轮：对剩余 10 条候选 PMID 做 PubMed 标题级复核

本轮不再做抽象分类，而是把 10 条 PMID 逐一查到 PubMed 题名，用题名证据验证上一轮“均为原始临床研究”的结论。

复核结果

- 33977284 — ''Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.''
- 结论：保留；明确是随机临床试验
- 22367193 — ''A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.''
- 结论：保留；单次给药对照研究，属于原始临床研究
- 29408453 — ''A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.''
- 结论：保留；RCT
- 22115710 — ''A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema.''
- 结论：保留；随机剂量递增研究
- 35040506 — ''mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.''
- 结论：保留；主试验 + longitudinal analysis 不构成排除
- 25525171 — ''Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial.''
- 结论：保留；phase I/II 临床试验
- 24618547 — ''Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.''
- 结论：保留；pilot trial
- 18037627 — ''Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study.''
- 结论：保留；proof-of-concept 原始研究
- 27613521 — ''Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.''
- 结论：保留；phase 3 RCT
- 29992557 — ''Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.''
- 结论：保留；single-arm phase IIIB trial

新增可复用判定

- 题名中出现 ''phase'' / ''randomized'' / ''double-blind'' / ''placebo-controlled'' / ''pilot'' / ''proof-of-concept'' / ''single-arm'' / ''dose-escalation'' 时，默认倾向于原始临床研究，而不是排除。
- 仅凭题名中的 ''longitudinal analysis'' 不能排除；若它附着在主试验后，仍归为主试验的附带分析。
- 对“看起来不像长寿研究”的药物适应症（如眼科、肺高压、癫痫、肿瘤）不要先验排斥；只要是原始临床试验，就应保留到更高层的长寿相关性筛选阶段。

这轮的实际推进

- 把 10 条候选从“研究类型审计”推进到“PubMed 标题证据复核”
- 消除了对个别边界病例的含糊性，特别是 single-dose、single-arm、proof-of-concept、dose-escalation 这类标题
- 下一步可将这 10 条进一步映射到“与衰老/寿命干预的相关性强弱”分层，而不是停留在是否为原始研究的层面